{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:34:56Z","timestamp":1783398896430,"version":"3.54.6"},"reference-count":90,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Hexal AG"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Data indicate that earlier initiation of anti-tumor necrosis factor alpha (anti-TNF-\u03b1) biologic medicines may prevent progression to irreversible bowel damage and improve outcomes for patients with inflammatory bowel disease (IBD), particularly Crohn\u2019s disease. However, the high cost of such therapies may restrict access and prevent timely treatment of IBD. Biosimilar anti-TNF-\u03b1 medicines may represent a valuable opportunity for cost savings and optimized patient outcomes by improving access to advanced therapies and allowing earlier anti-TNF-\u03b1 treatment initiation. Biosimilar anti-TNF-\u03b1 medicines have been shown to offer consistent therapeutic outcomes to their reference medicines, yet despite entering the IBD treatment armamentarium over 10 years ago, their implementation in clinical practice remains suboptimal. Factors limiting the \u2018real\u2019 use of biosimilar anti-TNF-\u03b1 medicines may include an ongoing lack of understanding and acceptance of biosimilars by both healthcare professionals (HCPs) and patients, as well as systemic factors such as formulary decisions outside of the control of the prescriber. In this review, an expert panel of gastroenterologists discusses HCP-level considerations to improve biosimilar anti-TNF-\u03b1 utilization in IBD in order to support early anti-TNF-\u03b1 initiation and maximize patient outcomes.<\/jats:p>","DOI":"10.3390\/jcm14051561","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T04:46:37Z","timestamp":1740545197000},"page":"1561","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Accelerating Earlier Access to Anti-TNF-\u03b1 Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5623-2968","authenticated-orcid":false,"given":"Gionata","family":"Fiorino","sequence":"first","affiliation":[{"name":"IBD Unit, San Camillo-Forlanini Hospital, 00152 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Ananthakrishnan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell D.","family":"Cohen","sequence":"additional","affiliation":[{"name":"University of Chicago Medicine, Chicago, IL 60637, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond K.","family":"Cross","sequence":"additional","affiliation":[{"name":"The Melissa L. Posner Institute for Digestive Health & Liver Disease at Mercy Medical Center, Baltimore, MD 21202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parakkal","family":"Deepak","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Washington University School of Medicine in St. Louis, St. Louis, MO 63110, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis A.","family":"Farraye","sequence":"additional","affiliation":[{"name":"Mayo Clinic Florida, Jacksonville, FL 32224, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0122-7234","authenticated-orcid":false,"given":"Jonas","family":"Halfvarson","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Faculty of Medicine and Health, \u00d6rebro University, SE-701 82 \u00d6rebro, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4781-9601","authenticated-orcid":false,"given":"A. Hillary","family":"Steinhart","sequence":"additional","affiliation":[{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/j.gastro.2021.04.063","article-title":"Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User\u2019s Guide for Adult and Pediatric Gastroenterologists","volume":"161","author":"Agrawal","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e065186","DOI":"10.1136\/bmjopen-2022-065186","article-title":"Global, Regional and National Burden of Inflammatory Bowel Disease in 204 Countries and Territories from 1990 to 2019: A Systematic Analysis Based on the Global Burden of Disease Study 2019","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"s1","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology Consensus Guidelines on the Management of Inflammatory Bowel Disease in Adults","volume":"68","author":"Lamb","year":"2019","journal-title":"Gut"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S2468-1253(21)00312-5","article-title":"Comparative Efficacy and Safety of Biologic Therapies for Moderate-to-Severe Crohn\u2019s Disease: A Systematic Review and Network Meta-Analysis","volume":"6","author":"Singh","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.5009\/gnl14226","article-title":"Current and Emerging Biologics for Ulcerative Colitis","volume":"9","author":"Park","year":"2015","journal-title":"Gut Liver"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.14309\/ajg.0000000000002498","article-title":"Baseline Clinical Factors Are Associated with Risk of Complications in Crohn\u2019s Disease: Appraisal of the American Gastroenterological Association Clinical Care Pathway","volume":"119","author":"Santiago","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Adegbola, S.O., Sahnan, K., Warusavitarne, J., Hart, A., and Tozer, P. (2018). Molecular Sciences Anti-TNF Therapy in Crohn\u2019s Disease. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19082244"},{"key":"ref_8","unstructured":"Troein, P., Newton, M., Stoddart, K., and Arias, A. (2023, September 11). The Impact of Biosimilar Competition in Europe. Available online: https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/library\/white-papers\/the-impact-of-biosimilar-competition-in-europe-2022.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Baumgart, D.C., Misery, L., Naeyaert, S., and Taylor, P.C. (2019). Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?. Front. Pharmacol., 10.","DOI":"10.3389\/fphar.2019.00279"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4292\/wjgpt.v8.i2.114","article-title":"Inflammatory Bowel Disease: Efficient Remission Maintenance Is Crucial for Cost Containment","volume":"8","author":"Actis","year":"2017","journal-title":"World J. Gastrointest. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1093\/ibd\/izz059","article-title":"The Role of Early Biologic Therapy in Inflammatory Bowel Disease","volume":"25","author":"Berg","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1007\/s12325-020-01437-4","article-title":"Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review","volume":"37","author":"Rezk","year":"2020","journal-title":"Adv. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"D\u2019Amico, F., Peyrin-Biroulet, L., and Danese, S. (2024). Benefits of Biosimilars in the Management of Patients with Inflammatory Bowel Disease: An International Survey. J. Clin. Med., 13.","DOI":"10.3390\/jcm13113069"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s40259-022-00546-6","article-title":"Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies","volume":"36","author":"Cohen","year":"2022","journal-title":"BioDrugs"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Car, E., Vulto, A.G., Van Houdenhoven, M., Huys, I., and Simoens, S. (2023). Biosimilar Competition in European Markets of TNF-Alpha Inhibitors: A Comparative Analysis of Pricing, Market Share and Utilization Trends. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1151764"},{"key":"ref_16","unstructured":"European Medicines Agency (2023, September 11). European Commission Biosimilars in the EU\u2014Information Guide for Healthcare Professionals. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf."},{"key":"ref_17","unstructured":"(2023, September 07). Government of Canada Handbook for Healthcare Professionals on Biosimilar Biologic Drugs. Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/biosimilar-biologic-drugs\/handbook-healthcare-professionals.html."},{"key":"ref_18","unstructured":"US Food and Drug Administration (2024, August 20). FDA-Approved Biosimilar Products, Available online: https:\/\/www.fda.gov\/drugs\/biosimilars\/biosimilar-product-information."},{"key":"ref_19","unstructured":"GaBI Online (2024, August 20). Biosimilars Approved in Europe. Available online: https:\/\/www.gabionline.net\/biosimilars\/general\/biosimilars-approved-in-europe."},{"key":"ref_20","unstructured":"GI Society: Canadian Society of Intestinal Research (2024, August 20). Biologics and Biosimilars Available in Canada. Available online: https:\/\/badgut.org\/information-centre\/a-z-digestive-topics\/biologics-in-canada\/."},{"key":"ref_21","unstructured":"European Medicines Agency (2024, June 20). Uzpruvo (Ustekinumab). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/uzpruvo-epar-medicine-overview_en.pdf."},{"key":"ref_22","unstructured":"European Medicines Agency (2024, June 20). Pzychiva (Ustekinumab). Available online: https:\/\/www.ema.europa.eu\/en\/documents\/overview\/pyzchiva-epar-medicine-overview_en.pdf."},{"key":"ref_23","unstructured":"Pearce IP (2024, June 20). Amgen Launches Second Stelara\u00ae (Ustekinumab) Biosimilar in Canada. Available online: https:\/\/www.pearceip.law\/2024\/03\/04\/amgen-launches-second-stelara-ustekinumab-biosimilar-in-canada\/."},{"key":"ref_24","unstructured":"Government of Canada (2024, June 20). Drug and Health Product Submissions Under Review (SUR): New Drug Submissions Under Review. Available online: https:\/\/www.canada.ca\/en\/health-canada\/services\/drug-health-product-review-approval\/submissions-under-review\/new-drug-submissions-under-review.html#tbl1."},{"key":"ref_25","unstructured":"Polpharma Biologics (2024, June 20). Biosimilar Pipeline. Available online: https:\/\/polpharmabiologics.com\/en\/pipeline-portfolio\/biosimilar-pipeline."},{"key":"ref_26","unstructured":"US Food and Dug Administration (2025, January 15). Biosimilars: Overview for Health Care Professionals, Available online: https:\/\/www.fda.gov\/drugs\/biosimilars\/overview-health-care-professionals#What%20is%20a%20biosimilar%20product."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.5009\/gnl19209","article-title":"Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries","volume":"14","author":"Banerjee","year":"2020","journal-title":"Gut Liver"},{"key":"ref_28","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, and Center for Biologics Evaluation and Research (2015). Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Guidance for Industry."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1007\/s10620-019-05504-x","article-title":"Timely Use of Biologics in Early Crohn\u2019s Disease: The Return of \u201cHit Hard and Early\u201d?","volume":"64","author":"Danese","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_30","first-page":"2079582","article-title":"Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study","volume":"2016","author":"Ma","year":"2016","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Solitano, V., Zacharopoulou, E., Peyrin-Biroulet, L., and Danese, S. (2020). Clinical Medicine Early Intervention in Ulcerative Colitis: Ready for Prime Time?. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082646"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of Tight Control Management on Crohn\u2019s Disease (CALM): A Multicentre, Randomised, Controlled Phase 3 Trial","volume":"390","author":"Colombel","year":"2017","journal-title":"Lancet"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/apt.13139","article-title":"Randomised Clinical Trial: Deep Remission in Biologic and Immunomodulator Na\u00efve Patients with Crohn\u2019s Disease\u2014A SONIC Post Hoc Analysis","volume":"41","author":"Colombel","year":"2015","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.crohns.2012.05.015","article-title":"Subgroup Analysis of the Placebo-Controlled CHARM Trial: Increased Remission Rates through 3 Years for Adalimumab-Treated Patients with Early Crohn\u2019s Disease","volume":"7","author":"Schreiber","year":"2012","journal-title":"J. Crohns Colitis"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/ecco-jcc\/jjy223","article-title":"Efficacy and Safety of Adalimumab by Disease Duration: Analysis of Pooled Data from Crohn\u2019s Disease Studies","volume":"13","author":"Panaccione","year":"2019","journal-title":"J. Crohns Colitis"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1053\/j.gastro.2021.04.022","article-title":"AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn\u2019s Disease","volume":"160","author":"Feuerstein","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG Clinical Guideline: Management of Crohn\u2019s Disease in Adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am. J. Gastroenterol."},{"key":"ref_38","unstructured":"(2023, September 07). CADTH Technology Review: Optimal Use 360 Report Appropriate Pharmacotherapy for Inflammatory Bowel Disease. Available online: https:\/\/www.cadth.ca\/sites\/default\/files\/hta-he\/ho0003-he0018-ibd-ou360.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A Biomarker-Stratified Comparison of Top-down versus Accelerated Step-up Treatment Strategies for Patients with Newly Diagnosed Crohn\u2019s Disease (PROFILE): A Multicentre, Open-Label Randomised Controlled Trial","volume":"9","author":"Noor","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target Strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"14","author":"Torres","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_43","first-page":"2","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"2022","author":"Raine","year":"2021","journal-title":"J. Crohns Colitis"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/jcag\/gwz019","article-title":"Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn\u2019s Disease","volume":"2","author":"Panaccione","year":"2019","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1053\/j.gastro.2015.03.001","article-title":"Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus","volume":"148","author":"Bressler","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG Clinical Guideline: Ulcerative Colitis in Adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am. J. Gastroenterol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1177\/2050640619853448","article-title":"Cost-of-illness of Inflammatory Bowel Disease Patients Treated with Anti-tumour Necrosis Factor: A French Large Single-centre Experience","volume":"7","author":"Lawton","year":"2019","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2468-1253(21)00252-1","article-title":"Safety and Efficacy of BI 695501 versus Adalimumab Reference Product in Patients with Advanced Crohn\u2019s Disease (VOLTAIRE-CD): A Multicentre, Randomised, Double-Blind, Phase 3 Trial","volume":"6","author":"Hanauer","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_49","first-page":"392","article-title":"Infliximab Biosimilar CT-P13 Is Effective and Safe in Treating Inflammatory Bowel Diseases: A Real-Life Multicenter, Observational Study in Italian Primary Inflammatory Bowel Disease Centers","volume":"32","author":"Tursi","year":"2019","journal-title":"Ann. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"D\u2019Amico, F., Solitano, V., Magro, F., Olivera, P.A., Halfvarson, J., Rubin, D., Dignass, A., Al Awadhi, S., Kobayashi, T., and Queiroz, N.S.F. (2023). Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus. J. Clin. Med., 12.","DOI":"10.20944\/preprints202308.2094.v1"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"151939","DOI":"10.1016\/j.semarthrit.2021.11.009","article-title":"The Cost Savings of Biosimilars Can Help Increase Patient Access and Lift the Financial Burden of Health Care Systems","volume":"52","author":"Kvien","year":"2022","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"The Lancet Rheumatology (2021). NICE guidance for moderate RA-a step in the right direction. Lancet Rheumatol., 3, e533.","DOI":"10.1016\/S2665-9913(21)00226-5"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e14341","DOI":"10.1111\/ijcp.14341","article-title":"Comparing Cost of Intravenous Infusion and Subcutaneous Biologics in COVID-19 Pandemic Care Pathways for Rheumatoid Arthritis and Inflammatory Bowel Disease: A Brief UK Stakeholder Survey","volume":"75","author":"Heald","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_54","unstructured":"European Specialist Nurses Organisation (2023, September 11). A Communication and Information Guide for Nurses: Switch Management Between Similar Biological Medicines. Available online: https:\/\/www.esno.org\/assets\/files\/Biosimilars%20Guideline%20V2%20EN.pdf."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cgh.2018.08.064","article-title":"Switching Between Biologics and Biosimilars in Inflammatory Bowel Disease","volume":"17","author":"Raffals","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/ecco-jcc\/jjw198","article-title":"ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease\u2014An Update","volume":"11","author":"Danese","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/14712598.2023.2189008","article-title":"Recommendations on TNF\u03b1 Inhibitor Biosimilar Use in Clinical Practice: A Comparison of European Gastroenterology IBD Guidance","volume":"23","author":"Meijboom","year":"2023","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.dld.2023.09.003","article-title":"Timing of Proper Introduction, Optimization and Maintenance of Anti-TNF Therapy in IBD: Results from a Delphi Consensus","volume":"56","author":"Ardizzone","year":"2024","journal-title":"Dig. Liver Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/ecco-jcc\/jjw090","article-title":"Changes in Biosimilar Knowledge among European Crohn\u2019s Colitis Organization [ECCO] Members: An Updated Survey","volume":"10","author":"Danese","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"6294","DOI":"10.3748\/wjg.v23.i34.6294","article-title":"Access to Biologicals in Crohn\u2019s Disease in Ten European Countries","volume":"23","author":"Lakatos","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Barcina Lacosta, T., Vulto, A.G., Huys, I., and Simoens, S. (2023). An Exploration of Biosimilar TNF-Alpha Inhibitors Uptake Determinants in Hospital Environments in Italy, Portugal, and Spain. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1029040"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1093\/jcag\/gwad015","article-title":"The 2023 Impact of Inflammatory Bowel Disease in Canada: Treatment Landscape","volume":"6","author":"Murthy","year":"2023","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"ref_63","first-page":"7365937","article-title":"Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease","volume":"2017","author":"Rumman","year":"2017","journal-title":"Can. J. Gastroenterol. Hepatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"17562848231169652","DOI":"10.1177\/17562848231169652","article-title":"Barriers to Optimizing Inflammatory Bowel Disease Care in the United States","volume":"16","author":"Spencer","year":"2023","journal-title":"Therap. Adv. Gastroenterol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.14309\/ajg.0000000000002720","article-title":"Insurance Companies\u2019 Poor Adherence to Guidelines for Moderate-to-Severe Ulcerative Colitis\/Crohn\u2019s Disease Management","volume":"119","author":"Anderson","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1001\/jamainternmed.2020.3188","article-title":"Uptake of Infliximab Biosimilars Among the Medicare Population","volume":"180","author":"Chen","year":"2020","journal-title":"JAMA Intern. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40744-017-0085-z","article-title":"Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect","volume":"4","author":"Rezk","year":"2017","journal-title":"Rheumatol. Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.12998\/wjcc.v10.i14.4327","article-title":"Emerging Role of Biosimilars in the Clinical Care of Inflammatory Bowel Disease Patients","volume":"10","author":"Najeeb","year":"2022","journal-title":"World J. Clin. Cases"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40259-023-00620-7","article-title":"Patients\u2019 Perceptions of Biosimilars: A Systematic Review","volume":"37","author":"Wu","year":"2023","journal-title":"BioDrugs"},{"key":"ref_70","unstructured":"European Medicines Agency (2023, July 12). Statement on the Scientific Rationale Supporting Interchangeability of Biosimilar Medicines in the EU. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/public-statement\/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf."},{"key":"ref_71","unstructured":"U.S. Department of Health and Human Services Food and Drug Administration, Center for Drug Evaluation and Research (CDER), and Center for Biologics Evaluation and Research (CBER) (2023, September 14). Considerations in Demonstrating Interchangeability with a Reference Product: Guidance for Industry, Available online: https:\/\/www.fda.gov\/media\/124907\/download."},{"key":"ref_72","unstructured":"Arad, N., Hamilton Lopez, M., Ray, R., Dentzer, S., Kroetsch, A., McClellan, M., and Wosinka, M. (2024, September 30). Realizing the Benefits of Biosimilars: What the US Can Learn from Europe. Available online: https:\/\/healthpolicy.duke.edu\/sites\/default\/files\/2021-04\/Realizing%20the%20Benefits%20of%20Biosimilars.pdf."},{"key":"ref_73","first-page":"215","article-title":"Biosimilar Uptake: The Importance of Healthcare Provider Education","volume":"35","author":"Oskouei","year":"2021","journal-title":"Pharmaceut. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"e023603","DOI":"10.1136\/bmjopen-2018-023603","article-title":"Healthcare Professionals\u2019 Perceptions and Perspectives on Biosimilar Medicines and the Barriers and Facilitators to Their Prescribing in UK: A Qualitative Study","volume":"8","author":"Aladul","year":"2018","journal-title":"BMJ Open"},{"key":"ref_75","first-page":"141","article-title":"Patients\u2019 Perceive Biologics to Be Riskier and More Dreadful Than Other IBD Medications","volume":"26","author":"Haron","year":"2020","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1097\/MIB.0000000000001110","article-title":"Patient Understanding of the Risks and Benefits of Biologic Therapies in Inflammatory Bowel Disease: Insights from a Large-Scale Analysis of Social Media Platforms","volume":"23","author":"Martinez","year":"2017","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/PPA.S32690","article-title":"Patient Perspectives on the Impact of Crohn\u2019s Disease: Results from Group Interviews","volume":"6","author":"Norton","year":"2012","journal-title":"Patient Prefer. Adherence"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/17474124.2021.1898944","article-title":"Patients with Inflammatory Bowel Disease (IBD) Prefer Oral Tablets over Other Modes of Medicine Administration","volume":"15","author":"Denesh","year":"2021","journal-title":"Expert. Rev. Gastroenterol. Hepatol."},{"key":"ref_79","first-page":"147","article-title":"Patients Perception of Risks and Benefits of Biologic Therapy","volume":"26","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s40615-022-01282-x","article-title":"Exploring Biologic Treatment Hesitancy Among Black and Indigenous Populations in Canada: A Review","volume":"10","author":"Udounwa","year":"2023","journal-title":"J. Racial Ethn. Health Disparities"},{"key":"ref_81","unstructured":"US Food & Drug Administration (2023, September 11). Interchangeable Biological Products, Available online: https:\/\/www.fda.gov\/media\/151094\/download."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/ecco-jcc\/jjw138","article-title":"Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn\u2019s and Ulcerative Colitis Associations","volume":"11","author":"Roblin","year":"2017","journal-title":"J. Crohns Colitis"},{"key":"ref_83","unstructured":"The Arthritis Society (2023, September 08). Biosimilar Focus Group Project Report. Available online: https:\/\/arthritis.ca\/AS\/media\/pdf\/About%20Arthritis\/TAS_FocusGroupReport_Final_ENG_V5.pdf."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"S418","DOI":"10.14309\/00000434-201710001-00750","article-title":"Patient Perceptions Regarding the Use of Biosimilars in Inflammatory Bowel Disease: 750","volume":"112","author":"Pineles","year":"2017","journal-title":"Am. J. Gastroenterol."},{"key":"ref_85","first-page":"343","article-title":"An Online Survey among US Patients with Immune-Mediated Conditions: Attitudes about Biosimilars","volume":"29","author":"Gibofsky","year":"2023","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_86","unstructured":"Dudley, M., Kojinkov, M., Baraga, D., Donnet, X., Gro\u00df, E., Lantzanaki, S., de Kwaadsteniet, T.M., McArdle, T., Mossakowska, M., and Perovic, M. (2024, June 21). ECCO-EFCCA Patient Guidelines on Crohn\u2019s Disease (CD). Available online: https:\/\/efcca.org\/sites\/default\/files\/Crohn%C2%B4s%20Disease%20Patient%20Guidelines.pdf."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Vandenplas, Y., Simoens, S., Van Wilder, P., Vulto, A.G., and Huys, I. (2021). Informing Patients about Biosimilar Medicines: The Role of European Patient Associations. Pharmaceuticals, 14.","DOI":"10.3390\/ph14020117"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.dld.2019.11.004","article-title":"Multidisciplinary Management of the Nocebo Effect in Biosimilar-Treated IBD Patients: Results of a Workshop from the NOCE-BIO Consensus Group","volume":"52","author":"Pouillon","year":"2020","journal-title":"Dig. Liver Dis."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40259-022-00548-4","article-title":"The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease","volume":"36","author":"Dutt","year":"2022","journal-title":"BioDrugs"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1093\/ibd\/izaa364","article-title":"Outcome of Reverse Switching from CT-P13 to Originator Infliximab in Patients with Inflammatory Bowel Disease","volume":"27","author":"Mahmmod","year":"2021","journal-title":"Inflamm. Bowel Dis."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1561\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:42:49Z","timestamp":1760028169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/5\/1561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":90,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["jcm14051561"],"URL":"https:\/\/doi.org\/10.3390\/jcm14051561","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]}}}